AB 001

Drug Profile

AB 001

Alternative Names: AB-001

Latest Information Update: 03 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ABsize
  • Developer Frontier Biotechnologies
  • Class Anti-inflammatories; Nonsteroidal anti-inflammatories
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Back pain

Most Recent Events

  • 03 Aug 2017 AB 001 is still in phase-II clinical development in Back pain in USA (Frontier Bioechnologies website, August 2017)
  • 22 Jun 2016 Efficacy and adverse events data from a phase II trial in Back pain released by Frontier Biotech
  • 01 Apr 2015 Phase-II clinical trials in Back pain in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top